The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of LENZ Therapeutics Inc (NASDAQ: LENZ) was $38.61 for the day, down -0.46% from the previous closing price of $38.79. In other words, the price has decreased by -$0.46 from its previous closing price. On the day, 1.45 million shares were traded. LENZ stock price reached its highest trading level at $40.49 during the session, while it also had its lowest trading level at $37.9.
Ratios:
Our analysis of LENZ’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 20.54 and its Current Ratio is at 20.54. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On March 18, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $60.
On September 27, 2024, Raymond James started tracking the stock assigning a Outperform rating and target price of $37.Raymond James initiated its Outperform rating on September 27, 2024, with a $37 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 30 ’25 when Versant Venture Capital VI, L. sold 132,944 shares for $46.01 per share. The transaction valued at 6,117,323 led to the insider holds 1,050,599 shares of the business.
Versant Venture Capital VI, L. sold 92,030 shares of LENZ for $4,234,695 on Sep 30 ’25. The 10% Owner now owns 764,127 shares after completing the transaction at $46.01 per share. On Sep 18 ’25, another insider, Versant Venture Capital VI, L., who serves as the 10% Owner of the company, sold 90,654 shares for $42.23 each. As a result, the insider received 3,828,632 and left with 1,183,543 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LENZ now has a Market Capitalization of 1181769344 and an Enterprise Value of 892770112. For the stock, the TTM Price-to-Sale (P/S) ratio is 220.25 while its Price-to-Book (P/B) ratio in mrq is 5.33. Its current Enterprise Value per Revenue stands at 178.554 whereas that against EBITDA is -14.43.
Stock Price History:
The Beta on a monthly basis for LENZ is 0.62, which has changed by 0.47197866 over the last 52 weeks, in comparison to a change of 0.1443547 over the same period for the S&P500. Over the past 52 weeks, LENZ has reached a high of $50.40, while it has fallen to a 52-week low of $16.53. The 50-Day Moving Average of the stock is -4.26%, while the 200-Day Moving Average is calculated to be 26.95%.
Shares Statistics:
LENZ traded an average of 588.97K shares per day over the past three months and 1197790 shares per day over the past ten days. A total of 28.50M shares are outstanding, with a floating share count of 24.40M. Insiders hold about 14.45% of the company’s shares, while institutions hold 92.31% stake in the company. Shares short for LENZ as of 1759190400 were 5269801 with a Short Ratio of 8.95, compared to 1756425600 on 4951564. Therefore, it implies a Short% of Shares Outstanding of 5269801 and a Short% of Float of 34.22.
Earnings Estimates
The stock of LENZ Therapeutics Inc (LENZ) is currently drawing attention from 5.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.77, with high estimates of -$0.63 and low estimates of -$0.87.
Analysts are recommending an EPS of between -$2.15 and -$2.75 for the fiscal current year, implying an average EPS of -$2.55. EPS for the following year is -$2.5, with 6.0 analysts recommending between -$1.75 and -$3.65.
Revenue Estimates
Based on 8 analysts’ estimates, the company’s revenue will be $49.12M in the next fiscal year. The high estimate is $60.28M and the low estimate is $39.6M.
